Abstract
The v-ets oncoprotein and its progenitor Ets1 belong to a family of transcription factors that are related by an 85 amino acid conserved DNA binding domain, the ets domain. Ets1 plays important role(s) in control of cell proliferation, differentiation and apoptosis. Abnormal expression of Ets1 could lead to disruption of these processes and contribute to development of malignancy. Retinoic acid (RA) inhibits proliferation, induces differentiation and regulates apoptosis in many different cell types. Here, we demonstrate that RA treatment increases the expression of Ets1 mRNA, but not that of Ets2, Elk1 or Fli1 in MC3T3-E1 cells. Ets1 induction is detectable after 4 h, can be maintained for at least 14 days, and is inhibited by Actinomycin D, which suggests that RA regulation of Ets1 occurs at the transcriptional level. The promoter region of Ets1 contains four retinoic acid response element (RARE) half sites located at −94, −152, −1765 and −2252 from the translation start site. We show that RARβ is expressed by MC3T3-E1 cells in the presence of RA and demonstrate that it binds to the −94 RARE half site. Furthermore, RA induces transcription of Ets1 promoter-reporter constructs containing this RARE half site.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 50 print issues and online access
$259.00 per year
only $5.18 per issue
Rent or buy this article
Prices vary by article type
from$1.95
to$39.95
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Bellacosa A, Datta K, Bear SE, Patriotis C, Lazo PA, Copeland NG, Jenkins NA and Tsichlis PN . 1994 J Virol 68: 2320–2330
Bhat NK, Fisher RJ, Fujiwara S, Ascione R and Papas TS . 1987 Proc Natl Acad Sci USA 84: 3161–3165
Chen Z, Fisher RJ, Riggs CW, Rhim JS and Lautenberger JA . 1997 Cancer Res 57: 2013–2019
Chomczynski P and Sacchi N . 1987 Anal Biochem 162: 156–159
Davidoff AN and Mendelow BV . 1994 Anticancer Res 14: 1199–1201
Ducy P, Zhang R, Geoffroy V, Ridall AL and Karsenty G . 1997 Cell 89: 747–754
Gilles F, Raes MB, Stehelin D, Vandenbunder B and Fafeur V . 1996 Exp Cell Res 222: 370–378
Glass CK, Devary OV and Rosenfeld MG . 1990 Cell 63: 729–738
Greenberg ME, Hermanowski AL and Ziff EB . 1986 Mol Cell Biol 6: 1050–1057
Hart AH, Corrick CM, Tymms MJ, Hertzog PJ and Kola I . 1995 Oncogene 10: 1423–1430
Hoosein NM, Brattain DE, McKnight MK, Childress KE, Chakrabarty S and Brattain MG . 1988 Cancer Lett 40: 219–232
Inoue A, Otsuka E, Hiruma Y, Hirose S, Furuya M, Tanaka S and Hagiwara H . 1996 Biochem Biophys Res Commun 228: 182–186
Janknecht R and Nordheim A . 1993 Biochim Biophys Acta 1155: 346–356
Jorcyk CL, Garrett LJ, Maroulakou IG, Watson DK and Green JE . 1997 Cell Mol Biol, Noisy-le-grand 43: 211–225
Jorcyk CL, Watson DK, Mavrothalassitis GJ and Papas TS . 1991 Oncogene 6: 523–532
Karperien M, Farih-Sips H, Lowik CW, de Laat SW, Boonstra J and Defize LH . 1997 Mol Endocrinol 11: 1434–1448
Kim WY, Sieweke M, Ogawa E, Wee HJ, Englmeier U, Graf T and Ito Y . 1999 EMBO J 18: 1609–1620
Kola I, Brookes S, Green AR, Garber R, Tymms M, Papas TS and Seth A . 1993 Proc Natl Acad Sci USA 90: 7588–7592
LaRosa GJ and Gudas LJ . 1988 Mol Cell Biol 8: 3906–3917
Lau LF and Nathans D . 1987 Proc Natl Acad Sci USA 84: 1182–1186
Leid M, Kastner P and Chambon P . 1992 Trends Biochem Sci 17: 427–433
Linney E . 1992 Curr Top Dev Biol 27: 309–350
Lohnes D, Mark M, Mendelsohn C, Dolle P, Dierich A, Gorry P, Gansmuller A and Chambon P . 1994 Development 120: 2723–2748
Mahadevan LC and Edwards DR . 1991 Nature 349: 747–748
Majerus MA, Bibollet-Ruche F, Telliez JB, Wasylyk B and Bailleul B . 1992 Nucleic Acids Res 20: 2699–2703
Mangelsdorf DJ, Borgmeyer U, Heyman RA, Zhou JY, Ong ES, Oro AE, Kakizuka A and Evans RM . 1992 Genes Dev 6: 329–344
Maroulakou IG, Papas TS and Green JE . 1994 Oncogene 9: 1551–1565
Niles RM, Wilhelm SA, Thomas P and Zamcheck N . 1988 Cancer Invest 6: 39–45
Oka T, Rairkar A and Chen JH . 1991 Oncogene 6: 2077–2083
Seth A, Ascione R, Fisher RJ, Mavrothalassitis GJ, Bhat NK and Papas TS . 1992 Cell Growth Differ 3: 327–334
Seth A and Papas TS . 1990 Oncogene 5: 1761–1767
Seth A, Watson DK, Blair DG and Papas TS . 1989 Proc Natl Acad Sci USA 86: 7833–7837
Sharrocks AD, Brown AL, Ling Y and Yates PR . 1997 Int J Biochem Cell Biol 29: 1371–1387
Sun W, Graves BJ and Speck NA . 1995 J Virol 69: 4941–4949
Suva LJ, Ernst M and Rodan GA . 1991 Mol Cell Biol 11: 2503–2510
Suva LJ, Towler DA, Harada S, Gaub MP and Rodan GA . 1994 Mol Endocrinol 8: 1507–1520
Suzuki H, Romano-Spica V, Papas TS and Bhat NK . 1995 Proc Natl Acad Sci USA 92: 4442–4446
Thiele CJ, Deutsch LA and Israel MA . 1988 Oncogene 3: 281–288
Wang DY, Yang VC and Chen JK . 1997 In Vitro Cell Dev Biol Anim 33: 248–255
Wasylyk B, Hahn SL and Giovane A . 1993 Eur J Biochem 211: 7–18
Watson DK, Ascione R and Papas TS . 1990 Crit Rev Oncog 1: 409–436
Acknowledgements
This work was supported by a Medical Research Council (Canada) group grant to A Seth.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Raouf, A., Li, V., Kola, I. et al. The Ets1 proto-oncogene is upregulated by retinoic acid: characterization of a functional retinoic acid response element in the Ets1 promoter. Oncogene 19, 1969–1974 (2000). https://doi.org/10.1038/sj.onc.1203505
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.onc.1203505
Keywords
This article is cited by
-
Prediction of osteoporosis candidate genes by computational disease-gene identification strategy
Journal of Human Genetics (2008)
-
Direct and indirect effects of retinoic acid on human Th2 cytokine and chemokine expression by human T lymphocytes
BMC Immunology (2006)
-
SP100 inhibits ETS1 activity in primary endothelial cells
Oncogene (2005)
-
Ets transcription factors and targets in osteogenesis
Oncogene (2000)